Clinical application of growth factors and cytokines in wound healing

Wound Repair and Regeneration - Tập 22 Số 5 - Trang 569-578 - 2014
Stephan Barrientos1, Harold Brem1, Olivera Stojadinović2, Marjana Tomic‐Canic3,4,5,2
1Division of Wound Healing and Regenerative Medicine, Department of Surgery, Winthrop University Hospital/Stony Brook University School of Medicine, Mineola, New York
2Wound Healing and Regenerative Medicine Research Program, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.
3Prof. Marjana Tomic-Canic, Department of Dermatology, University of Miami Miller School of Medicine, 2023A RMSB, 1600 N.W. 10th Avenue, Miami, FL 33136, USA.
4Reprint requests:
5Tel: 305 243 4940

Tóm tắt

Abstract

Wound healing is a complex and dynamic biological process that involves the coordinated efforts of multiple cell types and is executed and regulated by numerous growth factors and cytokines. There has been a drive in the past two decades to study the therapeutic effects of various growth factors in the clinical management of nonhealing wounds (e.g., pressure ulcers, chronic venous ulcers, diabetic foot ulcers). For this review, we conducted an online search of Medline/PubMed and critically analyzed the literature regarding the role of growth factors and cytokines in the management of these wounds. We focused on currently approved therapies, emerging therapies, and future research possibilities. In this review, we discuss four growth factors and cytokines currently being used on and off label for the healing of wounds. These include granulocyte‐macrophage colony‐stimulating factor, platelet‐derived growth factor, vascular endothelial growth factor, and basic fibroblast growth factor. While the clinical results of using growth factors and cytokines are encouraging, many studies involved a small sample size and are disparate in measured endpoints. Therefore, further research is required to provide definitive evidence of efficacy.

Từ khóa


Tài liệu tham khảo

10.1046/j.1524-475x.2000.00013.x

10.1084/jem.176.5.1375

10.1677/erc.0.0070165

Center for Disease Control and Prevention.National diabetes fact sheet 2011. Available at:http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf(accessed February 19 2013).

Brown G, 2003, Long‐term outcomes of full thickness pressure ulcers: healing and mortality, Ostomy Wound Manage, 49, 42

10.1016/j.amjsurg.2009.12.021

Russo A, 2008, Hospitalizations related to pressure ulcers among adults 18 years and older, 2006

10.1016/j.metabol.2005.04.016

10.2119/2007-00132.Finnerty

10.1016/j.cyto.2008.10.005

10.1007/BF02899530

Yomen A, 1996, Effects of granulocyte colony stimulating factor in the treatment of diabetic foot infection, J Invest Dermatol, 107, 404

10.1046/j.1365-2133.1998.02360.x

10.1046/j.0022-202x.2001.01600.x

10.1084/jem.175.6.1717

Schriber J, 1993, The efficacy of granulocyte colony‐stimulating factor following autologous bone marrow transplantation for non‐Hodgkin's lymphoma with monoclonal antibody purged bone marrow, Leukemia, 7, 1491

10.1111/j.1365-2796.1994.tb00834.x

10.1038/sj.bmt.1703566

Visani G, 1990, Accelerated hemopoietic recovery after chemotherapy and autologous bone marrow transplantation in hematological malignancies using recombinant GM‐CSF; preliminary results obtained in14 cases, Hematologica, 75, 551

Gorin N, 1992, Recombinant human granulocyte‐macrophage colony stimulating factor after high dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non‐Hodgkin's lymphoma: A double blind placebo controlled trial, Blood, 80, 1149, 10.1182/blood.V80.5.1149.1149

10.1097/00000658-200211000-00020

10.1111/j.1365-2133.2007.07979.x

10.1111/j.1365-2133.2009.09528.x

10.1007/s00595-005-3097-1

10.1111/j.1349-7006.2008.00761.x

10.1097/01.sap.0000096449.71981.1b

10.1097/00005373-199512000-00023

10.3109/10837459709022622

Bayer Pharmacuticals.Leukine 2009.http://www.pharma.bayer.com/scripts/pages/en/news_room/news_room/news_room79.php(accessed May 30 2013).

10.1046/j.1524-475x.1999.00017.x

10.1016/S0002-9610(97)89589-X

10.1046/j.1365-4362.1999.00665.x

10.1097/00000658-200004000-00020

10.1016/S0163-4453(97)91809-0

10.1016/S0140-6736(97)04495-4

West N, 1995, Systemic antimicrobial treatment of foot infections in diabetic patients, Am J Health Syst Pharm, 52, 1199, 10.1093/ajhp/52.11.1199

10.1046/j.1468-3083.2002.00526.x

10.1111/j.1524-475X.2009.00526.x

Wang Z, 2008, Effect of recombinant human granulocyte‐macrophage colony stimulating factor on wound healing in patients with deep partial thickness burn, Zhonghua Shao Shang Za Zhi, 24, 107

10.1111/j.1365-2133.2005.06925.x

10.4103/2229-5151.124168

10.1097/00006534-199807000-00018

10.1152/physrev.1999.79.4.1283

10.1126/science.277.5323.242

Sundberg C, 1997, Tumor cell and connective tissue cell interaction in human colorectal adenocarcinoma. Transfer of platelet‐derived growth factor‐AB/BB to stromal cells, Am J Pathol, 151, 479

10.1016/0014-5793(96)00408-5

10.1016/S0022-4804(02)96485-1

10.1016/j.biomaterials.2006.07.023

10.1083/jcb.200505175

10.1046/j.1524-475X.1997.50106.x

10.1046/j.1524-475X.1996.40404.x

Food and Drug Administration.Regranex 2008http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM142821.pdf(accessed May 30 2013).

D'Hemecourt P, 1998, Sodium carboxymethylcellulose aquesous‐based gel vs. becapleermin gel in patients with nonhealing lower extremity diabetic ulcers, Wounds, 10, 69

10.1016/S0741-5214(95)70245-8

10.2337/diacare.21.5.822

10.1016/0741-5214(91)90247-R

10.1046/j.1524-475X.1999.00335.x

10.1111/j.1524-475X.2005.00074.x

10.1097/00000637-199209000-00001

10.1046/j.1524-475X.1999.00141.x

10.1001/archsurg.1994.01420260109015

10.1038/mt.2009.169

10.1046/j.1524-475x.2000.00460.x

10.1046/j.1524-475X.1999.00148.x

10.1046/j.1524-475x.2000.00036.x

10.1046/j.1523-1747.2003.12112.x

10.1111/j.1524-475X.2008.00410.x

10.1002/bjs.4019

10.1001/archsurg.1996.01430180086018

10.1016/j.yexcr.2007.03.013

10.1111/j.0022-202X.2004.22323.x

10.1007/s004030050429

10.1677/erc.0.0070165

10.1111/j.1743-6109.2006.00143.x

10.1016/S0379-0738(00)00218-8

10.1111/j.1743-6109.2006.00120.x

10.1111/j.1346-8138.1992.tb03755.x

10.1097/00000658-199210000-00002

10.1111/j.1524-475X.2011.00726.x

10.1016/S0002-9610(00)00536-5

10.2337/diacare.18.1.64

Uchi H, 2009, Clinical Efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcers, Eur J Dermatol, 19, 461, 10.1684/ejd.2009.0750

10.1016/S0140-6736(98)01260-4

Nie K, 2010, Clinical observation of basic fibroblast growth factor combined with topical oxygen therapy in enhancing burn wound healing, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 24, 643

Guo H, 2009, Effects of perforated bovine amnion combined with recombinant bovine basic fibroblast growth factor on degree II burn wounds: a comparison with imperforated bovine amnion and Vaseline gauze dressing, J Clin Rehab Tissue Eng Res, 13, 10193

Chang F, 2009, Gene gun‐delivered human basic fibroblast growth factor gene facilitates the healing of deep partial thickness burn wounds, J Clin Rehab Tissue Eng Res, 13, 4611

10.2741/2277

10.1074/jbc.M606878200

10.1046/j.1524-475x.2001.00347.x

Robson M, 2004, Healing of chronic venous ulcers is not enhanced by the addition of topical repifermin (KGF‐2) to standardized care, J Appl Res, 4, 302

10.2353/ajpath.2006.051251

10.1074/jbc.271.46.29393

Suzuma K, 1998, Hypoxia and vascular endothelial growth factor stimulate angiogenic integrin expression in bovine retinal microvascular endothelial cells, Invest Ophthalmol Vis Sci, 39, 1028

Senger D, 1996, Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanism involving the alphavbeta3 integrin, osteopontin, and thrombin, Am J Pathol, 149, 293

Morbidelli L, 1996, Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium, Am J Physiol, 270, H411

10.1016/0006-291X(92)92277-5

Goto F, 1993, Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels, Lab Invest, 69, 508

10.1038/sj.onc.1201033

Nissen N, 1998, Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing, Am J Pathol, 152, 1445

10.1038/bjc.1998.158

10.1182/blood.V90.10.4153

10.1091/mbc.3.2.211

10.1016/j.freeradbiomed.2005.11.016

10.1097/00005344-199601000-00015

10.1016/S0741-5214(95)70272-5

Bauters C, 1994, Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb, Am J Physiol, 267, 1263

Takeshita S, 1995, Intramuscular administration of vascular endothelial growth factor induces dose‐dependent collateral artery augmentation in a rabbit model of chronic limb ischemia, Circulation, 90, 228

10.1172/JCI117018

10.1016/S0002-9440(10)63754-6

10.1084/jem.20021244

10.1038/80430

10.1089/hum.2006.17.683

10.12968/jowc.2008.17.1.27917

10.1046/j.1524-475X.1997.50108.x

10.1111/1523-1747.ep12359590

10.1111/1523-1747.ep12365637

10.1111/1523-1747.ep12612786

10.2119/2006-00054.Brem

Steed D, 1996, Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group, J Am Coll Surg, 183, 61

10.1097/00129334-200309000-00015

10.1046/j.1524-475X.2002.10603.x

10.1007/s00268-009-0024-4

10.1016/j.jamcollsurg.2008.09.018

10.2119/molmed.2009.00149

10.1186/1479-5876-6-75